GET DAILY SIGNALSCoherus Oncology (CHRS): Can Shares Climb +624% to the $7.75 Analyst Target?
Key Takeaways
- The central CHRS price target of $7.75 is the arithmetic mean of four current analyst price targets, which range from $4.00 to $10.00.
- The latest verified share price is $1.07, meaning the stock would need to rise roughly 624% to reach the $7.75 target — a very large move by any standard.
- Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company that has pivoted from biosimilars to immuno-oncology, with its anti-CCR8 pipeline at the center of the bull case.
- Supporting factors include expected revenue growth, upcoming clinical readouts, and a Strong Buy-leaning analyst consensus; the biggest risks are ongoing losses, cash burn, a history of estimate cuts, and delisting concerns.
- The wide target range reflects genuine disagreement about how to value a pre-profit oncology developer whose future hinges on clinical data.
- For additional context on the ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these dedicated pages.
- Explore Trending AI Robots to see AI-driven trading tools that monitor stocks and ETFs for changing market conditions.
Analyst Price Targets and Consensus View
CHRS represents Coherus Oncology, Inc. (formerly Coherus BioSciences, renamed in May 2025). Four current analyst price targets underpin the $7.75 central target: H.C. Wainwright's Douglas Tsao at $7.00, Maxim Group at $4.00, Guggenheim at $10.00 (lowered from $12.00 in August 2026), and Oppenheimer's Jay Olson at $10.00. The arithmetic mean of these four figures is $7.75, with a range of $4.00 to $10.00. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
That range is unusually wide, which itself is informative. The gap between the $4.00 and $10.00 targets reflects fundamentally different assumptions about how Coherus's lead clinical programs will perform rather than a consensus view. Guggenheim initiated coverage with a Buy in May 2026, citing the potential of CCR8-targeting immunotherapies, before trimming its target from $12.00 to $10.00. Ratings skew strongly toward Buy, with one Hold rating and no Sell ratings among the firms with published recommendations. Investors should treat the mean as a mathematical average, not a guarantee or an official published consensus.
Current Market Position and Path Toward the Target
At a recent close of $1.07, Coherus trades near the bottom of its 52-week range of $0.94 to $2.62, with a market capitalization of roughly $165 million. Reaching $7.75 would require a gain of approximately 624% — a very large move that would transform the company's valuation even before considering new share issuance. Such a move would almost certainly require clinical or regulatory catalysts, not incremental commercial execution alone.
The company reported trailing-twelve-month revenue near $50.9 million against a net loss of about $132 million, reflecting the cost of its oncology transition. Analysts project revenue to grow to roughly $60.8 million in fiscal 2026 and about $100 million in 2027, with losses expected to narrow but persist. That trajectory frames the path toward the target: the stock would need the market to re-rate a still-loss-making developer on the strength of pipeline data.
What Could Support a Move Toward the Target
The bull case rests on Coherus's immuno-oncology pipeline, particularly its anti-CCR8 antibody now named tagmokitug and the related CHS-114 program. Analysts have described CCR8 as a mechanism for tumor-selective depletion of regulatory T cells that could complement existing immunotherapies. Positive Phase 1b data in head and neck squamous cell carcinoma and biomarker research published in late 2025 have reinforced this thesis.
Additional support includes expected revenue acceleration, with fiscal 2026 sales forecast to grow over 40% and 2027 sales projected to rise about 65%, as well as the narrow but widening path toward profitability. A Strong Buy-leaning recommendation profile and several price targets far above the current price reflect optimism that clinical readouts could reset the valuation.
What Could Prevent the Target From Being Reached
The obstacles are substantial. Coherus remains deeply unprofitable, with persistent cash burn, a history of revenue-estimate cuts, and analyst notes flagging dilution from new share issuance. Analysts have repeatedly revised down revenue and EPS (earnings per share) forecasts, and the company received a Nasdaq deficiency notice in 2026 after its shares closed below $1.00 for an extended period — a reminder of the downside tail risk.
Clinical-stage investing also carries binary risk: disappointing trial data, regulatory setbacks, or financing overhangs could compress the valuation rather than expand it. Because targets are so far above the current price, even a meaningful rally could leave the stock well short of $7.75.
Technical Levels and Market Structure
The stock sits below both its 50-day and 200-day moving averages, which were recently near $1.22 and $1.54, respectively. The 52-week high of $2.62 is the first major resistance zone above current levels, followed by the psychological $3.00 area. On the downside, the $0.94 52-week low and the $1.00 round-number level are the key support areas to watch, with the $1.00 threshold also carrying significance given the delisting notice.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always publish a stated period. The most important near-term item is the company's quarterly earnings report scheduled for November 9, 2026, which may update guidance and cash position. Investors should also watch clinical data readouts for tagmokitug and CHS-114, any financing announcements, analyst target revisions, and updates on Nasdaq listing compliance.
Using AI Tools in My Research Process
In my own work following volatile names like this, I’ve found Tickeron’s AI Daily Buy/Sell Signals useful for tracking momentum shifts and generating real-time signals based on technical behavior and market conditions. The system helps monitor thousands of stocks and ETFs, surfacing potential changes in trend that complement traditional fundamental analysis. For event-driven names such as CHRS, these signals can highlight risk or opportunity points more efficiently than manual review alone.
Final Assessment
Can CHRS reach $7.75? The target is an average of four analyst price targets ranging from $4.00 to $10.00, and it implies a gain of roughly 624% from the recent $1.07 price — a very large move that would likely require transformative clinical or regulatory news rather than steady commercial progress. The strongest support comes from Coherus's CCR8-focused oncology pipeline and projected revenue growth, while the principal obstacles are persistent losses, cash burn, estimate cuts, and delisting risk. The unusually wide analyst range signals deep uncertainty about the company's trajectory, and no analyst target should be read as a forecast of what will happen. Investors should monitor clinical readouts, the November 9 earnings report, financing activity, and any analyst revisions before drawing conclusions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CHRS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 24, 2026
CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 39 of 43 cases where CHRS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CHRS's RSI Indicator exited the oversold zone, 29 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 71 cases where CHRS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CHRS as a result. In 59 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for CHRS just turned positive on October 22, 2026. Looking at past instances where CHRS's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
CHRS moved below its 50-day moving average on September 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CHRS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.717) is normal, around the industry mean (2.974). P/E Ratio (-1.019) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of biologic therapeutics for oncology and inflammatory diseases
Industry Biotechnology
Advertisement